Kidney Disease Study, Stouffville

About this study

Do you suffer from Chronic Kidney Disease?

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse.

This is a Phase IIb, randomised, multicentre, double-blind, parallel-group study aiming to determine the effect on albuminuria, as well as safety, of baxdrostat/dapagliflozin compared with baxdrostat/placebo, when given to participants with CKD and high blood pressure.

Study population will include participants ≥ 18 years old with CKD. Participants with or without a diagnosis of T2DM and with or without an SGLT2i treatment at screening are eligible for the study.

Would you like to take part in kidney disease research?

As a volunteer in a research study, you’ll receive study-related medical care from the study doctor and regular follow up of your condition to monitor the safety and effectiveness of the care you’ll receive. Study volunteers are an important part of moving medical care forward.

Who may qualify

You may qualify if

Are of any sex and gender, ≥ 18 years of age at the time of signing the informed consent.
Have an eGFR ≥ 30 and < 90 mL/min/1.73 m2 at screening
Have a UACR > 200 mg/g (22.6 mg/mmol) and < 5000 mg/g (565 mg/mmol) at screening
Have a history of HTN and a SBP ≥ 130 mmHg at screening and ≥ 120 mmHg at the randomisation visit.
Are on a stable and maximum daily tolerated dose of either an ACE inhibitor or an ARB (not both) for at least 4 weeks prior to the screening visit, if not medically contraindicated.
Have:
1. Serum or plasma potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR ≥ 45 mL/min/1.73 m2.
2. Serum or plasma potassium ≥ 3.0 and ≤ 4.5 mmol/L if eGFR < 45 mL/min/1.73 m2.

This study may not be a fit if

Have systolic blood pressure > 180 mmHg, or diastolic blood pressure > 110 mmHg at screening.
Have known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months before screening
Have serum sodium < 135 mmol/L at the Screening Visit (values obtained within 4 weeks prior to screening or at the Screening Visit).
Have diabetes mellitus:
1. T1DM at the screening visit
2. Uncontrolled T2DM at screening: HbA1C > 10.5% (> 91 mmol/mol)
Have New York Heart Association functional HF class IV at screening
Use mineralocorticoid receptor antagonists (such as spironolactone, eplerenone, or finerenone), aldosterone synthase inhibitors, potassium-sparing diuretics (such as triamterene or amiloride), or potassium binders (such as sodium zirconium cyclosilicate, patiromer, or sodium polystyrene sulfonate) within 4 weeks prior to screening
Have had a stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening HF within previous 3 months prior to randomization.
Have known severe hepatic impairment, defined as Child-Pugh Class C, based on records that confirm documented medical history.
Have any documented history of adrenal insufficiency.
Have had any dialysis (including for acute kidney injury) within 3 months prior to the screening
Have had any acute kidney injury within 3 months prior to the screening visit.
Are taking any prohibited concomitant medications

Every study has additional criteria the research site will review with you.

What participation may involve

Regular visits with the study team at no cost
Study assessments and health monitoring throughout
Check-ins between visits
Informed consent before anything begins — questions welcome

Time commitment: ≈3 months — confirmed by the research site. The full visit schedule is explained during informed consent.

What participants may receive

Study-related care from a physician-led team
Study assessments at no cost
Reimbursement for reasonable travel, where applicable

Specifics vary by study and site, and are never a guarantee of benefit. Being in a study is not a substitute for regular medical care.

Participating research sites

Where this study is enrolling

STOUFFVILLE, ONStouffville Medical CentrePrincipal investigator: Dr. Nima Mirtorabi, Dr. Sarah Barclay, Dr. Douglas WuView site →

Learn more

About the condition

Cardiovascular disease

Cardiovascular disease is a group of conditions affecting the heart and the blood vessels that carry blood around your body. The most common form in Canada is ischemic…

Learn about this condition →

About the condition

Chronic Kidney Disease

Your kidneys filter waste and extra fluid out of the blood, help control blood pressure, and keep minerals in balance. Chronic kidney disease means that filtering has been…

Learn about this condition →

About the condition

Hypertension (high blood pressure)

Blood pressure is the force of blood pushing against the walls of your arteries. Hypertension, or high blood pressure, means that force stays higher than it should over…

Learn about this condition →

About the condition

Kidney and Liver Diseases

The kidneys filter your blood and keep fluid and minerals in balance. The liver processes food, medicines and waste, and makes proteins your body needs every day. Both…

Learn about this condition →

Other studies you can explore

All current studies →

RecruitingStudy of Orforglipron in Participants With Peripheral Artery DiseaseMontrealCheck availability →

RecruitingA Study for Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney DiseaseSarnia · MontrealCheck availability →

RecruitingHypertension Study for Subjects With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseSarnia · MontrealCheck availability →

Common questions

Do I have to decide now?

No. Answering the questions is not a commitment — it simply lets the research team see whether this study may be appropriate and contact you to talk it through.

Will it cost me anything?

No. Study visits and study assessments are provided at no cost, and reasonable travel may be reimbursed where applicable.

What happens after I submit the form?

A member of the research team reviews your answers and contacts you — usually within two business days — to answer questions and review the next steps.

Could I receive a placebo?

Some studies compare a treatment with a placebo. Whether this study does is explained clearly during informed consent, before you decide anything.

Can I leave the study after it starts?

Yes. Participation is always voluntary. You can withdraw at any time without giving a reason and without it affecting your regular medical care.

Request contact

Ask the research site to contact you

Your answers go only to the research site, help the team prepare before they call — and completing the form doesn’t obligate you to take part.

JAS Study Interest (Stream A)

See if you may qualify

A few quick questions — about a minute. Your answers help the research team prepare before they contact you.

Who may take part in this study?

Myself

Someone I care for

Age of the person who may take part

For anyone under 18, a parent or legal guardian should complete this form and would need to consent on their behalf.

Has a doctor diagnosed you (or the person who may take part) with the condition this study is about?

Yes

Not sure

Postal code (first 3 characters are enough)

Study in Participants With Chronic Kidney Disease and High Blood Pressure

About this study

Who may qualify

What participation may involve

What participants may receive

Where this study is enrolling

Learn more

Cardiovascular disease

Chronic Kidney Disease

Hypertension (high blood pressure)

Kidney and Liver Diseases

Other studies you can explore

Common questions

Ask the research site to contact you

See if you may qualify

How can we reach you?

Find a study

Health Library

The network

Contact